Form 4: Celldex Therapeutics Director Harry Penner Jr. Granted 16,500 Stock Options

Celldex Therapeutics, Inc. Director Harry Penner Jr. was granted 16,500 non-qualified stock options with an exercise price of $19.53, exercisable from June 5, 2026, and expiring on June 5, 2035.

Summary

• Harry Penner Jr., a Director of Celldex Therapeutics, Inc. (CLDX), acquired 16,500 non-qualified stock options.
• The transaction date for the option grant was June 5, 2025.
• Each option has an exercise price of $19.53.
• These options become exercisable on June 5, 2026, and will expire on June 5, 2035.
• The options were granted under the Issuer's 2021 Omnibus Equity Incentive Plan.
• Following this transaction, Mr. Penner beneficially owns 16,500 derivative securities (options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal, indicating continued alignment of interests and incentivization. It's a routine compensation event rather than a major strategic announcement, hence a moderately positive score.

Positives

• The grant of stock options to a director aligns the director's interests with those of shareholders, as the options gain value if the stock price increases above the exercise price.
• This indicates continued commitment and incentivization of key management personnel.

Future Outlook

NA

Industry Context

This transaction is a routine compensation event for a director in the biotechnology industry, where equity incentives are common to attract and retain talent and align interests with long-term company performance.

Comparison to Industry Standards

• The grant of stock options to directors is a standard practice in the biotechnology and pharmaceutical industries, comparable to compensation structures seen at companies like BioNTech, Moderna, or Regeneron, where equity-based incentives are used to motivate leadership and align their financial interests with shareholder value creation.
• The specific number of options and exercise price would need to be benchmarked against peer companies of similar market capitalization and stage of development to assess if it's within typical ranges, but the mechanism itself is standard.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options aligns the director's financial interests with shareholder value creation, as the options become more valuable if the stock price increases.
• Employees: While not directly impacting employees, the use of an equity incentive plan suggests a broader framework for employee and director compensation.
• Management: The grant serves as an incentive for the director to contribute to the company's long-term success.

Next Steps

• The options granted to Harry Penner Jr. will become exercisable on June 5, 2026, at which point he may choose to exercise them, subject to market conditions and personal financial planning.

Key Dates

Recommendation

Keywords

Celldex Therapeutics, CLDX, Stock Options, Insider Trading, Form 4, Director Compensation, Equity Incentive Plan, Biotechnology, Pharmaceuticals